✦ LIBER ✦

A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer

✍ Scribed by Richard M. Lush, Amita Patnaik, Daniel Sullivan…

Book ID: 120776510
Publisher: Springer
Year: 2012
Tongue: English
Weight: 273 KB
Volume: 70
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-012-1942-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P78. Immediate reconstruction does not c

P78. Immediate reconstruction does not change the interval from surgery to chemotherapy in high risk breast cancer patients – An audit of a single breast unit

✍ Khan, Junaid; Barrett, Sophie; Reid, Iona; Winter-Wright, Alison; Weiler-Mithoff 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 38 KB

High dose single-agent paclitaxel in a h

High dose single-agent paclitaxel in a hemodialysis patient with advanced ovarian cancer: a case report with pharmacokinetic analysis and review of the literature

✍ M. BAUR; B. FAZENY-DOERNER; S.J. OLSEN; C. DITTRICH 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB

Superselective high-dose cisplatin infus

Superselective high-dose cisplatin infusion with concomitant radiotherapy in patients with advanced cancer of the nasal cavity and paranasal sinuses : A single institution experience

✍ Akihiro Homma; Nobuhiko Oridate; Fumiyuki Suzuki; Shigenari Taki; Takeshi Asano; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 287 KB 👁 1 views

## Abstract ## BACKGROUND: The current study aimed to evaluate the efficacy of superselective high‐dose cisplatin infusion with concomitant radiotherapy (RADPLAT) for previously untreated patients with advanced cancer of the nasal cavity and paranasal sinuses. ## METHODS: Between October 1999 an

Chemotherapy Dose Escalation Might Not I

Chemotherapy Dose Escalation Might Not Improve The Outcome Of Concurrent Chemo-radiation Treatment In Patients With Locally Advanced Head and Neck Cancer (LAHNC) Patients

✍ Skladowski, K.A.; Wygoda, A.; Cedrych, I.; Rutkowski, T.; Hutnik, M.; Pilecki, B 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 37 KB

1474 POSTER A phase I, open-label study

1474 POSTER A phase I, open-label study with escalating doses of intravenous PTK787/ZK 222584, a multi-VEGF receptor inhibitor, followed by multiple oral daily dosing to assess the absolute bioavailability of PTK787/ZK 222584 after single and multiple doses in advanced cancer patients

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 134 KB

Effect of comorbidity on risk of venous

Effect of comorbidity on risk of venous thromboembolism in patients with renal cell carcinoma11The project described was supported by the National Center for Research Resources, United States, through Grant KL2TR000084 the National Center for Advancing Translational Sciences, United States, through Grant KL2TR000084 and the National Institutes of Health, United States, through Grant KL2TR000084, and a grant from the Danish Cancer Society (R73-A4284-13-S17) and from the Karen Elise Jensen Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and the Clinical Epidemiological Research Foundation.

✍ Smith, Angela B.; Horvath-Puhó, Erzsébet; Nielsen, Matthew E.; Lash, Timothy L.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 220 KB